Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase I Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of RO7515629 in Patients With Unresectable and/or Metastatic HLA-G Positive Solid Tumors, Including Pancreatic Adenocarcinoma

Summary

The purpose of this phase I trial is to evaluate the safety and feasibility of RO7515629 in patients with solid tumors, including pancreatic cancer, expressing human leukocyte antigen G (HLA-G).

General Information

NCT#: NCT05769959
Study ID: BP44068
Trial Phase: Phase I

Trial Sponsor: Hoffmann-La Roche
Therapies Used in This Trial: RO7515629, Tocilizumab

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search